Compare LEE & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | KRRO |
|---|---|---|
| Founded | 1890 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.6M | 142.0M |
| IPO Year | 2025 | 2019 |
| Metric | LEE | KRRO |
|---|---|---|
| Price | $6.37 | $8.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | 32.7K | ★ 162.2K |
| Earning Date | 11-25-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $543,955,000.00 | $6,392,000.00 |
| Revenue This Year | $4.44 | N/A |
| Revenue Next Year | N/A | $56.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $3.34 | $5.20 |
| 52 Week High | $11.88 | $46.28 |
| Indicator | LEE | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 30.98 | 34.73 |
| Support Level | $5.01 | $8.29 |
| Resistance Level | $8.79 | $14.32 |
| Average True Range (ATR) | 0.37 | 0.75 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 1.64 | 9.43 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.